• Most Popular
  • Most Shared

UPDATE 1- Zeltia seeks European OK for ovarian cancer drug

Thu Dec 4, 2008 7:18am EST

Stocks

   

(Adds more details, share price)

MADRID, Dec 4 (Reuters) - Spanish pharmaceutical company Zeltia (ZEL.MC) said on Thursday it has submitted an application to the European Medicines Agency to approve its Yondelis drug for the treatment of ovarian cancer.

Zeltia said the drug would be used in the treatment of tumours in conjunction with Doxil-Caelyx.

At 1200 GMT, Zeltia shares were up 3.5 percent at 3.8 euros, compared with a 1.2 percent rise on the IBEX-35 (.IBEX).

Last month, Zeltia's partner in the United States, Johnson & Johnson's unit Orth Biotech Partners, filed for approval of Yondelis for ovarian cancer with the US Food and Drug Administration. (Reporting by Judy MacInnes; Editing by Erica Billingham)



More from Reuters

Photo

Fox, Time Warner Cable ink temp deal to avoid blackout

NEW YORK (Reuters) - Time Warner Cable and News Corp's Fox Networks agreed to a brief extension of their current carriage contract on Thursday to avoid a blackout that would have prevented 13 million U.S. homes from seeing TV shows like "The Simpsons" and college and NFL football games.

» More Top News
A customer is served at a counter inside a foreign exchange store displaying a poster of various banknotes including the Chinese yuan or renminbi (RMB) in Hong Kong November 20, 2009. REUTERS/Bobby Yip
OUTLOOK 2010:

Be careful what you wish for

Pressure on China to loosen its grip on the yuan will continue but the U.S. should tread carefully. Here are five world market issues to watch.  Full Article 

Global Markets
Clients work out on machines at the Bally Total Fitness facility in Arvada, Colorado June 15, 2009. REUTERS/Rick Wilking

Get real with resolutions

We make them and we break them: The secret to keeping them is to avoid the impossible dream.  Full Article 

Lifestyle